BUZZ-HK-listed Hbm climbs to six-week high on licence deal with Pfizer
I'm PortAI, I can summarize articles.
Hbm Holdings' shares surged 7.8% to a six-week high following a licensing deal with Pfizer. The agreement allows Pfizer global rights to Nona Biosciences' HCAb platform for antibody discovery, with Nona receiving upfront and potential milestone payments. This marks Hbm's largest intraday rise since September 30, with its stock up 676.9% year-to-date.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments